Thromboembolic disorders:
Indications for: KENGREAL
As adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Adult Dosage:
Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.
Children Dosage:
Not established.
KENGREAL Contraindications:
Significant active bleeding.
KENGREAL Warnings/Precautions:
Increased risk of bleeding. Discontinue 1hr prior to labor, delivery or neuraxial blockade. Pregnancy. Nursing mothers.
KENGREAL Classification:
P2Y12 platelet inhibitor (ATP analog).
KENGREAL Interactions:
Administer clopidogrel or prasugrel after infusion is discontinued.
Adverse Reactions:
Bleeding, renal impairment, dyspnea, hypersensitivity reactions.
Generic Drug Availability:
NO
How Supplied:
Single-use vial (10mL)—1, 10
